All-case post-marketing surveillance of delamanid for treating multidrug-resistant pulmonary tuberculosis in Japan
This surveillance showed the effectiveness of ≥6 months of delamanid treatment among patients with MDR-TB in real-world settings in Japan, with no new safety issues identified.
Authors
- Takefumi Saito
- Eriko Shigeto
- Hiroyuki HASHIZUME
- Toru Mori
- Satoshi Komaniwa
- Yuko Yamashige
- Hideaki Nagai
- Kyoko Suzue
- Takashi Yoshiyama
- Yuka Sasaki
- Kazunari Tsuyuguchi
Institutions
- Otsuka (Japan) (JP)
- Japan Anti Tuberculosis Association (JP)
- Higashihiroshima Medical Center (JP)
- Ibarakihigashi National Hospital (JP)
- Fukujuji Hospital (JP)
- Tokyo National Hospital (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
Publication Details
- Journal
- Respiratory Investigation
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1016/j.resinv.2025.101363
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00